Home > Medical Reference > Patient Education

Services at the UM Medical Center

See a complete list of Specialty Services and Departments at UMMC.

Brain tumors - primary

Description

An in-depth report on the causes, diagnosis, and treatment of brain tumors.


Alternative Names

Gliomas; Medulloblastoma


Radiotherapy

Radiotherapy plays a central role in the treatment of most brain tumors, whether benign or malignant.

Radiotherapy after Surgery. Even when it appears that the entire tumor has been surgically removed, microscopic cancer cells often remain in the surrounding brain tissue. Radiation targets the residual tumor with the goal of reducing its size or stopping its progression. If the entire tumor cannot be removed safely, postoperative radiotherapy is often recommended. Even some benign gliomas may require radiation, since they may be life-threatening if their growth is not controlled.

Radiotherapy When Surgery Is not Appropriate. Radiotherapy may be used instead of surgery for inaccessible tumors or for tumors that have properties that are particularly responsive to radiotherapy.

Radiotherapy and Chemotherapy (Radiochemotherapy). Combining chemotherapy with radiotherapy is beneficial in some patients with high-grade tumors.

Specific Radiation Treatments

Various radiation treatments are now available.

Conventional radiotherapy uses external beams aimed directly at the tumor and is usually recommended for large or infiltrating tumors. It begins about a week after surgery and continues 5 days per week for 6 weeks. Older adults have a more limited response to external-beam radiation therapy than younger people.

For tumors that are highly localized, the radiation therapist has a choice of other radiation treatments:

Stereotactic Radiosurgery

Stereotactic radiosurgery has been developed to allow highly targeted radiation to be delivered directly to the small tumors while avoiding healthy brain tissue. The term radiosurgery is used because the destruction is so precise that it acts almost like a surgical knife. Some studies suggest that stereotactic radiosurgery improves survival, even in patients with the highly aggressive glioblastoma multiforme brain cancer. The procedure is being tested to boost standard radiotherapy.

Benefits of Stereotaxy. There are numerous benefits for stereotaxy:

The Planning Procedure. Stereotactic radiosurgery usually begins with a series of steps designed to plan the radiation target:

Advanced imaging techniques are now allowing frameless stereotaxy , which eliminates the frame and may be effective on more tumors. For example, high-field interventional MR imaging (iMRI) uses a guidance system based on cruise-missile technology to calculate the slightest variations in movements of the head and the location of the tumor relative to these movements. These calculations are then used to target the radiation beams directly on the tumor, even if the patient's head is moving slightly.

Delivery of Radiation Beams. Once the preliminary planning stage has been completed, treatment begins. Several advanced machines, such as the gamma knife , adapted linear accelerator (LINAC) , and cyclotron , are being used with stereotaxy and can deliver very focused beams of radiation. Actual treatment takes 10 minutes to 1 hour.

Drugs Used With Radiation

Several drugs may be used along with radiation to increase the effectiveness of the treatment.

Radioprotectors. They protect healthy cells during radiation.

Radiosensitizers. These drugs make cancerous cells more sensitive to radiation. For example, combinations of the radiosensitive drugs iododeoxyuridine, 5-FU, and hydroxyurea are promising. Such treatments usually require aggressive use of other protective drugs to prevent severe side effects.

Radioenhancers. These drugs, such as topotecan, increase the effects of radiation. Topotecan combined with other drugs, such as thiotepa and carboplatin, may help children with neuroblastoma and brain tumors. A 2002 study using topotecan for glioblastoma multiforme was disappointing, but different methods of administration or other similar drugs may be useful. Efaproxiral, an investigative drug that increases oxygen in the brain, is showing promise as a radioenhancer.

Side Effects of Radiation

Common Side Effects. Side effects of radiotherapy include hair loss, nausea, vomiting, and fatigue. In some cases, radiation may worsen some existing symptoms of brain tumors, seizures, difficulty in swallowing, and movement problems. Fluid build-up (edema) may occur. Such side effects are usually temporary and treatable with steroids. Patients often develop problems in thinking and concentration after radiation treatments. One study suggested that administering oxygen under pressure, called hyperbaric oxygen, may provide some small benefits. It is sometimes difficult to tell symptoms of the disease from those of the treatments.

Tissue Injury. Radiation necrosis (total destruction of nearby healthy tissue) occurs in about 25% of patients treated with radiation. This condition is highly associated with reduction in mental functions. In nearly half the cases of standard radiation therapy, additional surgeries are needed on areas injured by radiation. Other treatments that are showing promise for treating necrotic tissue include administration of oxygen and pentoxifylline (a drug that improves blood flow).

Secondary Tumors. Of concern is a study reporting a few cases of second tumors developing in the areas treated with radiosurgery. The incidence appears to be very low, but experts suggest continued surveillance may be appropriate.

Specific Issues in Radiation Therapy for Small Children. In small children, radiation therapy can impair growth and learning. Precise radiation techniques, such as three-dimensional conformal radiation therapy, may help some children while limiting the injury to healthy brain tissue. Growth hormone is often used after radiotherapy and is effective in restoring growth in many of these children. Although there has been some concern that growth hormone may increase the risk of relapse, a 2000 study reported that, in fact, these children had a lower rate of recurrence than those who did not take growth hormone.


A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com